<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT923-8404</title>
	</head>
	<body>
		<main>
			<p>920812 FT  12 AUG 92 / International Company News: Swiss drugs group turns in 25.4% advance ARES-SERONO, the Swiss pharmaceutical group specialising in human fertility drugs, has reported a 25.4 per cent rise in net income from continuing operations to Dollars 38.6m in the first half. Sales were up 17.2 per cent to Dollars 415m. The group said pharmaceutical sales rose 21 per cent to Dollars 363.8m, with demand particularly strong in Italy, Germany and the US. Diagnostic product sales eased slightly to Dollars 51.3m, but excluding clinical chemistry sales, which are being discontinued, they rose 9 per cent. The group also had a Dollars 28.1m extraordinary gain from the sale of its over-the-counter drug division in the first half. In the second quarter, net income from continuing operations rose 25.6 per cent to Dollars 22m on sales up 18.7 per cent to Dollars 217m.</p>
		</main>
</body></html>
            